DermTech, Inc. (NASDAQ:DMTK) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC grew its holdings in DermTech, Inc. (NASDAQ:DMTKGet Rating) by 158.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 227,871 shares of the company’s stock after purchasing an additional 139,677 shares during the period. Rafferty Asset Management LLC’s holdings in DermTech were worth $3,600,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Advisor Group Holdings Inc. lifted its holdings in shares of DermTech by 14.7% in the 3rd quarter. Advisor Group Holdings Inc. now owns 4,719 shares of the company’s stock worth $152,000 after acquiring an additional 606 shares during the last quarter. US Bancorp DE boosted its position in shares of DermTech by 160.1% during the third quarter. US Bancorp DE now owns 1,009 shares of the company’s stock worth $32,000 after buying an additional 621 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of DermTech by 73.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,950 shares of the company’s stock valued at $63,000 after buying an additional 826 shares during the period. Royal Bank of Canada grew its position in DermTech by 13.1% in the 3rd quarter. Royal Bank of Canada now owns 8,803 shares of the company’s stock valued at $282,000 after acquiring an additional 1,018 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in shares of DermTech by 13.5% in the third quarter. Commonwealth Equity Services LLC now owns 9,037 shares of the company’s stock valued at $290,000 after purchasing an additional 1,075 shares during the period. 75.12% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $38.00 price objective (down from $48.00) on shares of DermTech in a research note on Thursday, April 14th. Zacks Investment Research cut DermTech from a “hold” rating to a “sell” rating in a research note on Thursday, April 21st. Craig Hallum cut their target price on shares of DermTech from $50.00 to $37.00 in a research note on Wednesday, March 2nd. Lake Street Capital reduced their target price on shares of DermTech from $79.00 to $34.00 in a report on Wednesday, March 2nd. Finally, Cowen lowered their price target on shares of DermTech from $33.00 to $20.00 in a report on Wednesday, May 4th.

In related news, CEO John Dobak sold 2,561 shares of DermTech stock in a transaction on Monday, March 7th. The shares were sold at an average price of $13.03, for a total value of $33,369.83. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Herm Rosenman purchased 20,000 shares of the company’s stock in a transaction dated Monday, May 9th. The shares were purchased at an average price of $6.86 per share, for a total transaction of $137,200.00. Following the completion of the purchase, the director now owns 72,832 shares of the company’s stock, valued at $499,627.52. The disclosure for this purchase can be found here. Insiders have sold a total of 7,037 shares of company stock worth $95,384 in the last 90 days. 3.60% of the stock is currently owned by company insiders.

DMTK stock opened at $7.37 on Tuesday. DermTech, Inc. has a twelve month low of $6.39 and a twelve month high of $48.32. The company’s 50 day moving average is $11.60 and its two-hundred day moving average is $15.04.

DermTech (NASDAQ:DMTKGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.12). DermTech had a negative net margin of 716.51% and a negative return on equity of 37.83%. During the same quarter in the previous year, the firm earned ($0.49) earnings per share. As a group, analysts predict that DermTech, Inc. will post -3.9 earnings per share for the current year.

DermTech Company Profile (Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Featured Stories

Want to see what other hedge funds are holding DMTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DermTech, Inc. (NASDAQ:DMTKGet Rating).

Institutional Ownership by Quarter for DermTech (NASDAQ:DMTK)

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.